Na Wang
Wuhan, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Long-term follow-up demonstrates the curative potential of dual CD19/CD22 CAR-T-cell therapy alone or combined with autologous stem cell transplantation in TP53-altered relapsed/refractory B-cell non-Hodgkin lymphoma.
Journal: Signal transduction and targeted therapy
Published: July 28, 2025
High-risk extranodal natural killer/T-cell lymphoma patients could benefit more from allogeneic hematopoietic stem cell transplantation as consolidation: A real-world multicenter analysis in China.
Journal: Chinese journal of cancer research = Chung-kuo yen cheng yen chiu
Published: June 26, 2025
Long-term Therapy Outcomes of CD19/22 CAR T Cell Alone or with Autologous Stem Cell Transplantation for Relapsed/Refractory DLBCL.
Journal: Blood cancer discovery
Published: November 18, 2024
Kdm2a inhibition in skeletal muscle improves metabolic flexibility in obesity.
Journal: Nature metabolism
Published: July 17, 2024
Prognostic differences between carmustine, etoposide, cytarabine and melphalan (BEAM) and carmustine, etoposide, cytarabine, melphalan and fludarabine (BEAMF) regimens before autologous stem cell transplantation plus chimeric antigen receptor T therapy in patients with refractory/relapsed B-cell non-Hodgkin-lymphoma.
Journal: Cytotherapy
Published: October 12, 2023
Efficacy and safety of chimeric antigen receptor T-cell therapy targeting CD19/CD22 in refractory/relapsed transformed aggressive B-cell lymphoma.
Journal: Cytotherapy
Published: May 14, 2022
T Cell Defects: New Insights Into the Primary Resistance Factor to CD19/CD22 Cocktail CAR T-Cell Immunotherapy in Diffuse Large B-Cell Lymphoma.
Journal: Frontiers in immunology
Published: February 11, 2022
Sequential CAR T-Cell Therapy After Autologous Stem Cell Transplantation for the Treatment of Relapsed/Refractory Intravascular Large B-Cell Lymphoma With Central Nervous System Involvement: A Case Report.
Journal: Frontiers in oncology
Published: December 05, 2021
A Reversible Chemogenetic Switch for Chimeric Antigen Receptor T Cells.
Journal: Angewandte Chemie (International ed. in English)
Published: July 16, 2021
CD19/CD22 Chimeric Antigen Receptor T Cell Cocktail Therapy following Autologous Transplantation in Patients with Relapsed/Refractory Aggressive B Cell Lymphomas.
Journal: Transplantation and cellular therapy
Published: May 22, 2021
Mutations or copy number losses of CD58 and TP53 genes in diffuse large B cell lymphoma are independent unfavorable prognostic factors.
Journal: Oncotarget
Published: September 24, 2015
Showing 1-12 of 12
Last Updated: 09/26/2026